Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy

Area of Science:

• Oncology
• Pharmacogenomics
• Neuroscience

Background:

• Pharmacogenomics aims to personalize cancer therapy by predicting individual drug responses and adverse effects.
• Chemotherapy-Induced Neurotoxicity (CIPN) is a severe, long-lasting side effect of anticancer drugs, significantly impacting patient Quality of Life (QoL).
• Current pharmacogenomics approaches for CIPN have yielded limited success, highlighting a need for methodological improvements.

Purpose of the Study:

• To analyze the limitations of current pharmacogenomics applications in predicting CIPN.
• To propose a collaborative framework integrating "bench-side" pharmacogenomics with "bed-side" clinimetrics.
• To enhance the effectiveness of genetic profiling for managing CIPN.

Main Methods:

• Review of existing pharmacogenomics studies related to CIPN.
• Analysis of methodological challenges in applying genetic profiling to clinical settings.
• Conceptual framework development for integrating molecular data with clinical observations.

Main Results:

• Current pharmacogenomics strategies for CIPN are often ineffective due to application errors.
• A significant gap exists between "bench-side" genetic discoveries and "bed-side" clinical utility.
• Cooperation between pharmacogenomics and clinimetrics is essential for successful genetic profiling.

Conclusions:

• Pharmacogenomics requires methodological refinement to effectively predict and manage CIPN.
• Integrating "bench-side" research with "bed-side" clinical practice is vital for personalized cancer therapy.
• A combined approach of pharmacogenomics and clinimetrics can improve patient outcomes and Quality of Life by mitigating CIPN.